All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Allarity Therapeutics Q3 net loss widens on one-time expense

By Reuters News


Overview

  • US clinical-stage pharma's Q3 net loss widened on one-time manufacturing expense for stenoparib API

  • Company expects positive Q4 earnings from gain on debt settlement, but full-year loss projected

  • First revenue-generating CLIA lab services contract signed; research capabilities expanded


Outlook

  • Allarity expects Q4 earnings of $0.01 to $0.04 per share

  • Company anticipates 2026 full-year loss between $0.73 and $0.76 per share

  • Company says Q4 earnings driven by one-time gain from debt extinguishment


Result Drivers

  • ONE-TIME MANUFACTURING EXPENSE - Co said $3.2 mln charge for stenoparib API manufacturing was main driver of higher R&D expenses and net loss in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$6.2 mln

Q3 Operating Expenses

$5.51 mln

Q3 Operating Income

-$5.51 mln


Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Allarity Therapeutics Inc is $11.00, about 1,103.8% above its November 12 closing price of $0.91


Reuters Recommended Reads

  • Nov 12 - Relmada Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

  • Nov 12 - Assembly Biosciences Q3 net loss widens on increased R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.